Dr Reddys Laboratories Ltd vs Gland Pharma Ltd Stock Comparison
Dr Reddys Laboratories Ltd vs Gland Pharma Ltd Stock Comparison
Last Updated on: May 03, 2026
Key Highlights
The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1322 as of 30 Apr 15:30
. The P/E Ratio of Dr Reddys Laboratories Ltd changed from 38.5 on March 2021 to 16.9 on March 2025 . This represents a CAGR of -15.18% over 5 yearsThe P/E Ratio of Gland Pharma Ltd changed from 40.7 on March 2021 to 37.5 on March 2025 . This represents a CAGR of -1.62% over 5 years The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 75095 crore on March 2021 to ₹ 95465 crore on March 2025 . This represents a CAGR of 4.92% over 5 yearsThe Market Cap of Gland Pharma Ltd changed from ₹ 40535 crore on March 2021 to ₹ 26232 crore on March 2025 . This represents a CAGR of -8.34% over 5 years The revenue of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 9024 crore as compare to the Sep '25 revenue of ₹ 9158 crore. This represent the decline of -1.46% The revenue of Gland Pharma Ltd for the Dec '25 is ₹ 1758 crore as compare to the Sep '25 revenue of ₹ 1571 crore. This represent the growth of 11.93% The ebitda of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 2158 crore as compare to the Sep '25 ebitda of ₹ 2340 crore. This represent the decline of -7.76% The ebitda of Gland Pharma Ltd for the Dec '25 is ₹ 473.7 crore as compare to the Sep '25 ebitda of ₹ 398.05 crore. This represent the growth of 19.01% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1392 crore to ₹ 1189 crore over 7 quarters. This represents a CAGR of -8.60%
The net profit of Gland Pharma Ltd changed from ₹ 143.76 crore to ₹ 261.48 crore over 7 quarters. This represents a CAGR of 40.75%
The Dividend Payout of Dr Reddys Laboratories Ltd changed from 19.03 % on March 2021 to 12.47 % on March 2025 . This represents a CAGR of -8.11% over 5 yearsThe Dividend Payout of Gland Pharma Ltd changed from 31.57 % on March 2024 to 27.22 % on March 2025 . This represents a CAGR of -7.14% over 2 years .
About Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe.
Its major markets include - USA, India, Russia & CIS countries, and Europe.
Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.
About Gland Pharma Ltd
Gland Pharma Limited was incorporated as Gland Pharma Private Limited', a private limited company on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad.
Subsequently, the name of the Company was changed to Gland Pharma Limited' and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.
The Company is primarily engaged in manufacturing injectable formulations.
Established in Hyderabad, India, Company has evolved into a prominent entity in the global generic injectables market, with operations extending to over 60 countries including the United States, Europe, Canada, Australia, and India.
Primarily functioning under a B2B model, the company provides comprehensive services such as contract development, dossier compilation, technology transfer, and manufacturing across various delivery systems.
FAQs for the comparison of Dr Reddys Laboratories Ltd and Gland Pharma Ltd
Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Gland Pharma Ltd?
Market cap of Dr Reddys Laboratories Ltd is 110,420 Cr while Market cap of Gland Pharma Ltd is 28,848 Cr
What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Gland Pharma Ltd?
The stock performance of Dr Reddys Laboratories Ltd and Gland Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Dr Reddys Laboratories Ltd and Gland Pharma Ltd?
As of May 3, 2026, the Dr Reddys Laboratories Ltd stock price is INR ₹1322.95. On the other hand, Gland Pharma Ltd stock price is INR ₹1751.0.
How do dividend payouts of Dr Reddys Laboratories Ltd and Gland Pharma Ltd compare?
To compare the dividend payouts of Dr Reddys Laboratories Ltd and Gland Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.